OGA

Summary

OGA (O-GlcNAcase, HGNC:7056) is a protein-coding gene on chromosome 10q24.32, encoding Protein O-GlcNAcase (O60502). Cleaves GlcNAc but not GalNAc from O-glycosylated proteins. It is a selective cancer dependency (DepMap: 11.5% of cell lines).

The dynamic modification of cytoplasmic and nuclear proteins by O-linked N-acetylglucosamine (O-GlcNAc) addition and removal on serine and threonine residues is catalyzed by OGT (MIM 300255), which adds O-GlcNAc, and MGEA5, a glycosidase that removes O-GlcNAc modifications (Gao et al., 2001 [PubMed 11148210]).

Source: NCBI Gene 10724 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 88 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 11.5% of screened cell lines
• MANE Select transcript: NM_012215

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7056
Approved symbol	OGA
Name	O-GlcNAcase
Location	10q24.32
Locus type	gene with protein product
Status	Approved
Aliases	MEA5, NCOAT
Ensembl gene	ENSG00000198408
Ensembl biotype	protein_coding
OMIM	604039
Entrez	10724

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 19 protein_coding, 6 protein_coding_CDS_not_defined

ENST00000357797, ENST00000361464, ENST00000370094, ENST00000429860, ENST00000439817, ENST00000461645, ENST00000462994, ENST00000479811, ENST00000482611, ENST00000492204, ENST00000494347, ENST00000883195, ENST00000883196, ENST00000883197, ENST00000883198, ENST00000883199, ENST00000883200, ENST00000883201, ENST00000883202, ENST00000883203, ENST00000883204, ENST00000928740, ENST00000928741, ENST00000928742, ENST00000928743

RefSeq mRNA: 2 — MANE Select: NM_012215 NM_001142434, NM_012215

CCDS: CCDS44471, CCDS7520

Canonical transcript exons

ENST00000361464 — 16 exons

Exon	Start	End
ENSE00000721914	101798842	101799455
ENSE00000721926	101810184	101810314
ENSE00000721929	101813030	101813127
ENSE00000721932	101813555	101813606
ENSE00000811427	101793913	101793998
ENSE00000811428	101800242	101800400
ENSE00000811429	101803735	101804019
ENSE00000811430	101806045	101806143
ENSE00003471052	101792839	101792943
ENSE00003531550	101807730	101807901
ENSE00003533549	101787364	101787523
ENSE00003538234	101791354	101791439
ENSE00003640803	101797980	101798154
ENSE00003691121	101790896	101791088
ENSE00003847848	101817824	101818444
ENSE00003848061	101784450	101786587

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.10.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 41.7872 / max 1031.2089, expressed in 1811 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
111108	36.4853	1807
111105	2.0225	904
111107	1.7255	970
111104	1.5539	618

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	99.10	gold quality
skin of abdomen	UBERON:0001416	98.64	gold quality
skin of leg	UBERON:0001511	98.64	gold quality
cerebellar hemisphere	UBERON:0002245	98.58	gold quality
cerebellar cortex	UBERON:0002129	98.56	gold quality
tibial nerve	UBERON:0001323	98.54	gold quality
right uterine tube	UBERON:0001302	98.49	gold quality
mucosa of stomach	UBERON:0001199	98.47	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.46	gold quality
left ovary	UBERON:0002119	98.44	gold quality
ventricular zone	UBERON:0003053	98.43	gold quality
colonic epithelium	UBERON:0000397	98.39	gold quality
cortical plate	UBERON:0005343	98.38	gold quality
descending thoracic aorta	UBERON:0002345	98.31	gold quality
ganglionic eminence	UBERON:0004023	98.30	gold quality
right ovary	UBERON:0002118	98.28	gold quality
calcaneal tendon	UBERON:0003701	98.28	gold quality
endocervix	UBERON:0000458	98.27	gold quality
male germ cell	CL:0000015	98.25	gold quality
cerebellum	UBERON:0002037	98.23	gold quality
ectocervix	UBERON:0012249	98.20	gold quality
right coronary artery	UBERON:0001625	98.11	gold quality
right lung	UBERON:0002167	98.10	gold quality
body of uterus	UBERON:0009853	98.10	gold quality
vagina	UBERON:0000996	98.03	gold quality
granulocyte	CL:0000094	97.99	gold quality
tendon	UBERON:0000043	97.99	gold quality
popliteal artery	UBERON:0002250	97.99	gold quality
tibial artery	UBERON:0007610	97.98	gold quality
nipple	UBERON:0002030	97.97	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-75367	no	2938.59
E-MTAB-6075	no	1398.35
E-GEOD-106540	no	593.49
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ALX1, AP1, AR, CREB1, DLX4, FOSB, FOXP3, GRHL3, IRF2, JUN, JUND, KAT5, KAT7, MEF2C, MYC, NCOA1, NFATC1, NFE2, NFKB, PDX1, RELA, SMARCA1, SMARCA5, SRF, TFAP2A, USF1

miRNA regulators (miRDB)

113 targeting OGA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-9718	99.94	68.91	918

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 11.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• This protein is a cytosolic, neutral, O-GlcNAc specific hexosaminidase termed O-GlcNAcase. (PMID:11148210)
• Investigated this locus in Pima Indians who have the world’s highest prevalence of NIDDM. Concluded that mutations in MGEA5 are unlikely to contribute to NIDDM in this population (PMID:12359146)
• In type 2 Diabetes patients in Mexico City, the frequency of the T allele of MGEAT5 was higher (2.6%) in the cases than in controls (1.8%), but not a significant deviation from Hardy_Weinberg proportions. (PMID:17546623)
• review of modifications, phosphorylation and a specific form of glycosylation, O-linked -N-acetylglucosaminylation by O-GlcNAc, relevant to pathological tau phosphorylation (PMID:18641620)
• the short nuclear variant of O-GlcNAcase, which has the identical catalytic domain as the full-length enzyme, has similar trends in a pH-rate profile and Taft linear free energy analysis as the full-length enzyme (PMID:19423084)
• characterization of O-GlcNAcase transition states using several series of substrates to generate multiple simultaneous free-energy relationships (PMID:19715310)
• This study analyzes the activity of the enzyme involved in the removal of these sugar residues, i.e. beta-N-acetylglucosaminidase (O-GlcNAcase) as well as the level of N-acetylglucosamine in benign and malignant thyroid lesions. (PMID:20198314)
• N-terminal region of OGA contains the catalytic site and the C-terminal region stabilizes the protein structure and affects substrate affinity. (PMID:20673219)
• Results provide evidence that OGA may possess a substrate-recognition mechanism tinvolving interactions with O-GlcNAcylated proteins beyond the GlcNAc-binding site. (PMID:20863279)
• Direct evidence links muscle atrophy and the disruption of O-GlcNAcase activity in male bitransgenic mice. (PMID:21178104)
• Reducing ChREBP(OG) levels via OGA overexpression decreased lipogenic protein content (ACC, FAS), prevented hepatic steatosis, and improved the lipidic profile of OGA-treated db/db mice. (PMID:21471514)
• Decrease in MGEA5 and increase in O-GlcNAc transferease expression in higher grade tumors suggests that increased O-GlcNAc modification may be implicated in breast tumor progression and metastasis. (PMID:21567137)
• Chromosomal translocation t(1;10) is consistent with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. (PMID:21717526)
• Data show that the interplay between O-GlcNAc and phosphorylation on proteins and indicate that these effects can be mediated by changes in hOGT and hOGA kinetic activity. (PMID:22311971)
• O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-beta-D-glucosaminidase silencing on cell phenotype and transcriptome. (PMID:22730328)
• Analysis of urinary content of MGEA5 and OGT may be useful for bladder cancer diagnostics. (PMID:22783592)
• Estrogen replacement therapy and plyometric training influence muscle OGT and OGA gene expression, which may be one of the mechanisms by which HRT and PT prevent aging-related loss of muscle mass. (PMID:24365779)
• Report the presence of TGFBR3 and/or MGEA5 rearrangements in pleomorphic hyalinizing angiectatic tumors and the spectrum of related neoplasms. (PMID:24705316)
• Amino acid composition of splice variants, post-translational modifications, and stable associations with regulatory proteins influence subcellular distribution/substrate specificity of OGA and OGT (O-linked N-acetylglucosamine transferase). [REVIEW] (PMID:25173736)
• This work identifies the first target of miR-539 in the heart and the first miRNA that regulates OGA. (PMID:25183011)
• OGA overexpression in endothelial cells improves endothelial function and may have a beneficial effect on coronary vascular complications in diabetes. (PMID:26269457)
• E2F1 negatively regulates both Ogt and Mgea5 expression in an Rb1 protein-dependent manner. (PMID:26527687)
• TGFBR3 and/or MGEA5 rearrangements are much more common in hybrid hemosiderotic fibrolipomatous tumor-myxoinflammatory fibroblastic sarcomas than in classical myxoinflammatory fibroblastic sarcomas. (PMID:26980036)
• the O-linked N-acetylglucosamine (O-GlcNAc) processing enzymes, O-GlcNAc-transferase (OGT) and O-GlcNAcase (OGA), interact with the (A)gamma-globin promoter at the -566 GATA repressor site (PMID:27231347)
• OGA is physically associated with the known RNA polymerase II (pol II) pausing/elongation factors SPT5 and TRIM28-KAP1-TIF1beta, and a purified OGA-SPT5-TIF1beta complex has elongation properties. (PMID:27601472)
• hOGA forms an unusual arm-in-arm homodimer in which the catalytic domain of one monomer is covered by the stalk domain of the sister monomer to create a substrate-binding cleft. (PMID:28319083)
• Data suggest that the substrate specificity of O-GlcNAcase/OGA does not extend to proteins/peptides modified with S-GlcNAc (an analog of O-GlcNAc); proteins modified with S-GlcNAc appear to be stable against O-GlcNAcase/OGA hydrolysis. (PMID:28627871)
• Tax interacts with the host OGT/OGA complex and inhibits the activity of OGT-bound OGA. (PMID:28742148)
• Beta-N-acetylhexosaminidase substrate recognition and specificity (PMID:28939839)
• OGT promotes carcinogenesis and metastasis of cervical cancer cells. OGT’s expression is significantly upregulated in cervical cancer, and low OGT level is correlated with improved prognosis (PMID:30052810)
• role of the tubular biomarkers NAG, kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in patients with chest pain before contrast media exposition (PMID:30920848)
• Study reports that OGA is upregulated in a wide range of human cancers and drives aerobic glycolysis and tumor growth by inhibiting pyruvate kinase M2 (PKM2). PKM2 is dynamically O-GlcNAcylated in response to changes in glucose availability. Under high glucose conditions, PKM2 is a target of OGA-associated acetyltransferase activity, which facilitates O-GlcNAcylation of PKM2 by O-GlcNAc transferase (OGT). (PMID:31501520)
• Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of alpha-synuclein preformed fibrils. (PMID:32365408)
• Involvement of NDPK-B in Glucose Metabolism-Mediated Endothelial Damage via Activation of the Hexosamine Biosynthesis Pathway and Suppression of O-GlcNAcase Activity. (PMID:33086728)
• Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice. (PMID:33310751)
• Elucidating the protein substrate recognition of O-GlcNAc transferase (OGT) toward O-GlcNAcase (OGA) using a GlcNAc electrophilic probe. (PMID:33333092)
• OGA is associated with deglycosylation of NONO and the KU complex during DNA damage repair. (PMID:34135314)
• Inhibition of O-GlcNAcase Inhibits Hematopoietic and Leukemic Stem Cell Self-Renewal and Drives Dendritic Cell Differentiation via STAT3/5 Signaling. (PMID:36124999)
• Cryo-EM structure of human O-GlcNAcylation enzyme pair OGT-OGA complex. (PMID:37907462)
• E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA. (PMID:38755129)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	oga	ENSDARG00000074686
mus_musculus	Oga	ENSMUSG00000025220
rattus_norvegicus	Oga	ENSRNOG00000017822
drosophila_melanogaster	Oga	FBGN0038870
caenorhabditis_elegans		WBGENE00020596

Protein

Protein identifiers

Protein O-GlcNAcase — O60502 (reviewed: O60502)

Alternative names: Beta-N-acetylglucosaminidase, Beta-N-acetylhexosaminidase, Beta-hexosaminidase, Meningioma-expressed antigen 5, N-acetyl-beta-D-glucosaminidase, N-acetyl-beta-glucosaminidase, Nuclear cytoplasmic O-GlcNAcase and acetyltransferase

All UniProt accessions (2): O60502, H7C3X0

UniProt curated annotations — full annotation on UniProt →

Function. Cleaves GlcNAc but not GalNAc from O-glycosylated proteins. Deglycosylates a large and diverse number of proteins, such as CRYAB, ELK1, GSDMD, LMNB1 and TAB1. Can use p-nitrophenyl-beta-GlcNAc and 4-methylumbelliferone-GlcNAc as substrates but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl-alpha-GlcNAc (in vitro). Does not bind acetyl-CoA and does not have histone acetyltransferase activity. Cleaves GlcNAc but not GalNAc from O-glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc as substrate but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl-alpha-GlcNAc (in vitro), but has about six times lower specific activity than isoform 1.

Subunit / interactions. Monomer. Interacts with CLOCK. (Microbial infection) Interacts with human T-cell leukemia virus 1/HTLV-1 protein Tax; this interaction increases Tax interacting partner CREB1 O-GlcNAcylation.

Subcellular location. Nucleus Cytoplasm.

Tissue specificity. Ubiquitous. Shows highest expression in the brain, placenta and pancreas.

Post-translational modifications. Proteolytically cleaved by caspase-3 during apoptosis. The fragments interact with each other; cleavage does not decrease enzyme activity.

Activity regulation. Inhibited by N-acetylglucosamine and not N-acetylgalactosamine.

Similarity. Belongs to the glycosyl hydrolase 84 family.

Isoforms (4)

UniProt ID	Names	Canonical?
O60502-1	1	yes
O60502-2	2
O60502-3	3, MGEA5s
O60502-4	4

RefSeq proteins (2): NP_001135906, NP_036347* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011496	O-GlcNAcase_cat	Domain
IPR016181	Acyl_CoA_acyltransferase	Homologous_superfamily
IPR017853	GH_hydrolase_sf	Homologous_superfamily
IPR051822	Glycosyl_Hydrolase_84	Family

Pfam: PF07555

Enzyme classification (BRENDA):

• EC 3.2.1.169 — protein O-GlcNAcase (BRENDA: 10 organisms, 123 substrates, 118 inhibitors, 78 Km, 29 kcat entries)
• EC 3.2.1.35 — hyaluronoglucosaminidase (BRENDA: 70 organisms, 156 substrates, 263 inhibitors, 27 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

24 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL N-ACETYL-BETA-D-GLUCOSAMINIDE	0.016–36	38
4-METHYLUMBELLIFERYL N-ACETYL-BETA-D-GLUCOSAMINI	0.0029–1.4	12
HYALURONAN	0.038–0.367	11
3,4-DINITROPHENYL N-ACETYL-BETA-D-GLUCOSAMINIDE	0.21–0.56	4
3-FLUORO-4-NITROPHENYL N-ACETYL-BETA-D-GLUCOSAMI	0.3–0.73	4
4-METHYLUMBELLIFERYL-N-ACETYL-BETA-D-GLUCOSAMINI	0.0029–0.1	3
3-NITROPHENYL N-ACETYL-BETA-D-GLUCOSAMINIDE	0.47–0.95	2
4-METHYLUMBELLIFERYL 2-ACETAMIDO-2-DEOXY-BETA-D-	0.08–1	2
FLUORESCEIN DI(N-ACETYL-BETA-D-GLUCOSAMINIDE)	0.0849–2.1	2
N-ACETYL-BETA-D-GLUCOSAMINE	1.5–3.6	2
PHENYL N-ACETYL-BETA-D-GLUCOSAMINIDE	0.62–0.95	2
4-CHLOROPHENYL N-ACETYL-BETA-D-GLUCOSAMINIDE	0.56	1
4-METHYLUMBELLIFERYL N-DIFLUOROACETYL-BETA-D-GLU	0.45	1
4-METHYLUMBELLIFERYL N-FLUOROACETYL-BETA-D-GLUCO	0.49	1
4-METHYLUMBELLIFERYL N-TRIFLUOROACETYL-BETA-D-GL	0.38	1

Catalyzed reactions (Rhea), 2 shown:

• 3-O-(N-acetyl-beta-D-glucosaminyl)-L-seryl-[protein] + H2O = N-acetyl-D-glucosamine + L-seryl-[protein] (RHEA:48876)
• 3-O-(N-acetyl-beta-D-glucosaminyl)-L-threonyl-[protein] + H2O = L-threonyl-[protein] + N-acetyl-D-glucosamine (RHEA:48892)

UniProt features (77 total): helix 20, turn 13, strand 13, mutagenesis site 10, binding site 7, splice variant 4, sequence variant 2, region of interest 2, chain 1, domain 1, site 1, modified residue 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

28 structures.

PDB	Method	Resolution (Å)
5UN8	X-RAY DIFFRACTION	2.13
5M7U	X-RAY DIFFRACTION	2.3
5M7R	X-RAY DIFFRACTION	2.35
5M7S	X-RAY DIFFRACTION	2.4
7OU6	X-RAY DIFFRACTION	2.41
5TKE	X-RAY DIFFRACTION	2.48
5UN9	X-RAY DIFFRACTION	2.5
8P0L	X-RAY DIFFRACTION	2.5
9BA8	X-RAY DIFFRACTION	2.54
2YDQ	X-RAY DIFFRACTION	2.6
5M7T	X-RAY DIFFRACTION	2.6
5VVO	X-RAY DIFFRACTION	2.6
5VVU	X-RAY DIFFRACTION	2.7
9BA9	X-RAY DIFFRACTION	2.75
5UHP	X-RAY DIFFRACTION	2.79
5VVT	X-RAY DIFFRACTION	2.8
5VVV	X-RAY DIFFRACTION	2.8
6PM9	X-RAY DIFFRACTION	2.86
5VVX	X-RAY DIFFRACTION	2.9
5UHK	X-RAY DIFFRACTION	2.97
9NE4	ELECTRON MICROSCOPY	2.98
9NE5	ELECTRON MICROSCOPY	3.05
9QEN	ELECTRON MICROSCOPY	3.08
5UHL	X-RAY DIFFRACTION	3.14
5UHO	X-RAY DIFFRACTION	3.21
6HKI	X-RAY DIFFRACTION	3.3
9NE2	ELECTRON MICROSCOPY	3.63
7YEH	ELECTRON MICROSCOPY	3.92

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60502-F1	76.02	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 413–414 (cleavage; by caspase-3); 175 (proton donor)

Ligand- & substrate-binding residues (7): 219; 285; 313; 67; 98; 174; 175

Post-translational modifications (1): 364

Mutagenesis-validated functional residues (10):

Position	Phenotype
69	strongly reduces affinity for glycopeptide substrates. nearly abolishes enzyme activity.
174	nearly abolishes enzyme activity.
175	nearly abolishes enzyme activity.
255	nearly abolishes enzyme activity.
286	nearly abolishes enzyme activity.
287	nearly abolishes enzyme activity.
413	abrogates cleavage by caspase-3.
679	nearly abolishes enzyme activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 209 (showing top): TGCGCANK_UNKNOWN, BASSO_B_LYMPHOCYTE_NETWORK, PEREZ_TP63_TARGETS, LFA1_Q6, MAZ_Q6, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, AP2_Q3, GGGTGGRR_PAX4_03, MODULE_229, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, UEDA_PERIFERAL_CLOCK, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, JIANG_TIP30_TARGETS_UP, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS

GO Biological Process (6): N-acetylglucosamine metabolic process (GO:0006044), protein O-linked glycosylation (GO:0006493), glycoprotein catabolic process (GO:0006516), protein deglycosylation (GO:0006517), glycoprotein metabolic process (GO:0009100), carbohydrate derivative metabolic process (GO:1901135)

GO Molecular Function (8): hyalurononglucosaminidase activity (GO:0004415), hexosaminidase activity (GO:0015929), identical protein binding (GO:0042802), [protein]-3-O-(N-acetyl-D-glucosaminyl)-L-serine/L-threonine O-N-acetyl-alpha-D-glucosaminase activity (GO:0102571), acyltransferase activity, transferring groups other than amino-acyl groups (GO:0016747), hydrolase activity (GO:0016787), hydrolase activity, acting on glycosyl bonds (GO:0016798), catalytic activity, acting on a protein (GO:0140096)

GO Cellular Component (4): nucleus (GO:0005634), cytosol (GO:0005829), membrane (GO:0016020), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
glycoprotein metabolic process	2
hydrolase activity, hydrolyzing O-glycosyl compounds	2
catalytic activity	2
amino sugar metabolic process	1
glycoprotein biosynthetic process	1
protein catabolic process	1
carbohydrate derivative catabolic process	1
protein modification process	1
protein metabolic process	1
carbohydrate derivative metabolic process	1
metabolic process	1
hexosaminidase activity	1
protein binding	1
catalytic activity, acting on a protein	1
acyltransferase activity	1
hydrolase activity	1
intracellular membrane-bounded organelle	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1752 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OGA	OGT	O15294	952
OGA	AURKB	Q96GD4	927
OGA	GM2A	P17900	857
OGA	GUSB	P08236	830
OGA	HEXB	P07686	814
OGA	B2M	P01884	775
OGA	HAVCR1	Q96D42	773
OGA	ARSB	P15848	761
OGA	GFPT2	O94808	758
OGA	GFPT1	Q06210	758
OGA	AMBP	P00977	728
OGA	ALB	P02768	720
OGA	LCN2	P30150	720
OGA	CST3	P01034	718
OGA	EP300	Q09472	712

IntAct

86 interactions, top by confidence:

A	B	Type	Score
EIF4E	EIF4G3	psi-mi:“MI:0914”(association)	0.810
C1QTNF9	C1QTNF9B	psi-mi:“MI:0914”(association)	0.780
CNOT3	CNOT1	psi-mi:“MI:0914”(association)	0.740
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
OGA	OGA	psi-mi:“MI:0407”(direct interaction)	0.610
OGA	OGA	psi-mi:“MI:0915”(physical association)	0.610
STN1	SMCO3	psi-mi:“MI:0914”(association)	0.530
SAMTOR	PER1	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
SPSB4	ARHGEF10	psi-mi:“MI:0914”(association)	0.530
OGA	TP53	psi-mi:“MI:0407”(direct interaction)	0.440
TNFAIP3	LRRIQ3	psi-mi:“MI:2364”(proximity)	0.420
XPO7	OGA	psi-mi:“MI:0915”(physical association)	0.400
LACTB2	OGA	psi-mi:“MI:0915”(physical association)	0.400
OGA	FKBP5	psi-mi:“MI:0915”(physical association)	0.400
OGA	NUDCD3	psi-mi:“MI:0915”(physical association)	0.400
OGA		psi-mi:“MI:0915”(physical association)	0.400
A2M	OGA	psi-mi:“MI:0915”(physical association)	0.370
OGA	CDC37	psi-mi:“MI:0915”(physical association)	0.370
MAST1	OGA	psi-mi:“MI:0915”(physical association)	0.370
RNF32	OGA	psi-mi:“MI:0915”(physical association)	0.370
CSNK2B	OGA	psi-mi:“MI:0915”(physical association)	0.370
GSK3B	OGA	psi-mi:“MI:0915”(physical association)	0.370
E7	COPE	psi-mi:“MI:0914”(association)	0.350
Xpo7	HAT1	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
CYLD	OGA	psi-mi:“MI:0914”(association)	0.350

BioGRID (160): MGEA5 (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), CDC37 (Co-fractionation), PITHD1 (Co-fractionation), MGEA5 (Affinity Capture-MS), MGEA5 (Proximity Label-MS), MGEA5 (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), MGEA5 (Affinity Capture-MS)

ESM2 similar proteins: A0JMD0, A1A535, A1ZAB5, A2AIV2, A8E7C5, A8PJX4, A8XAA9, B0W2S0, B3MIW0, B3NPV8, B4GAM1, B4JW99, B4KT50, B4LQ23, B4MY63, B4P6P7, D3YVL2, E9PXF8, F4HS99, F4HZK4, F4J5S1, F4JKH6, O60502, O75153, O88379, P34466, P69735, Q0IHW8, Q0VA04, Q15042, Q17N71, Q291J5, Q5PQS3, Q5SW19, Q5TYW4, Q5U430, Q69YN4, Q6NTN5, Q6ZT12, Q7PZD5

Diamond homologs: O60502, Q0TR53, Q2CEE2, Q2CEE3, Q89ZI2, Q8VIJ5, Q8XL08, Q9EQQ9, B3TLD6, P0DTR4, P29767, Q02834

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
OGA	“down-regulates activity”	G6PD	deglycosylation
OGA	“up-regulates activity”	PFKP	deglycosylation
OGA	“up-regulates activity”	PFKM	deglycosylation
OGA	“up-regulates activity”	PFKL	deglycosylation
OGA	“up-regulates activity”	PFK	deglycosylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

88 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	66
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

3028 predictions. Top by Δscore:

Variant	Effect	Δscore
10:101787358:ACTC:A	donor_loss	1.0000
10:101787360:TCA:T	donor_loss	1.0000
10:101787361:CA:C	donor_loss	1.0000
10:101787362:A:AC	donor_gain	1.0000
10:101787363:C:CC	donor_gain	1.0000
10:101787363:C:CG	donor_loss	1.0000
10:101787452:C:CT	acceptor_gain	1.0000
10:101787453:A:T	acceptor_gain	1.0000
10:101787520:TTTT:T	acceptor_gain	1.0000
10:101787524:C:CC	acceptor_gain	1.0000
10:101791344:TATC:T	donor_gain	1.0000
10:101791345:A:AC	donor_gain	1.0000
10:101791345:AT:A	donor_gain	1.0000
10:101791345:ATCA:A	donor_gain	1.0000
10:101791346:T:C	donor_gain	1.0000
10:101791352:A:AC	donor_gain	1.0000
10:101791353:C:CC	donor_gain	1.0000
10:101792942:CG:C	acceptor_gain	1.0000
10:101793574:CTAT:C	donor_gain	1.0000
10:101793688:AGAG:A	donor_gain	1.0000
10:101798061:T:TA	donor_gain	1.0000
10:101798840:A:AC	donor_gain	1.0000
10:101798841:C:CC	donor_gain	1.0000
10:101800240:A:AC	donor_gain	1.0000
10:101800241:C:CT	donor_gain	1.0000
10:101800241:CT:C	donor_gain	1.0000
10:101800241:CTG:C	donor_gain	1.0000
10:101800241:CTGCT:C	donor_gain	1.0000
10:101800271:TGCA:T	donor_gain	1.0000
10:101800398:CAG:C	acceptor_gain	1.0000

AlphaMissense

6069 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:101791044:A:T	V769D	1.000
10:101793946:C:A	W679C	1.000
10:101793946:C:G	W679C	1.000
10:101793948:A:G	W679R	1.000
10:101793948:A:T	W679R	1.000
10:101798031:A:G	W645R	1.000
10:101798031:A:T	W645R	1.000
10:101798145:A:G	W607R	1.000
10:101798145:A:T	W607R	1.000
10:101798897:A:G	L585P	1.000
10:101798951:A:G	L567P	1.000
10:101800278:A:G	W387R	1.000
10:101800278:A:T	W387R	1.000
10:101803778:C:A	W331C	1.000
10:101803778:C:G	W331C	1.000
10:101803780:A:G	W331R	1.000
10:101803780:A:T	W331R	1.000
10:101803808:G:C	N321K	1.000
10:101803808:G:T	N321K	1.000
10:101803826:A:C	N315K	1.000
10:101803826:A:T	N315K	1.000
10:101803830:G:C	P314R	1.000
10:101803830:G:T	P314Q	1.000
10:101803832:A:C	N313K	1.000
10:101803832:A:T	N313K	1.000
10:101803834:T:C	N313D	1.000
10:101803839:A:G	L311P	1.000
10:101803842:A:T	V310D	1.000
10:101803845:C:T	G309E	1.000
10:101803846:C:G	G309R	1.000

dbSNP variants (sampled 300 via entrez): RS1000059290 (10:101817285 G>A), RS1000224430 (10:101804565 G>A,T), RS1000234527 (10:101810934 G>A,T), RS1000349212 (10:101798596 T>C), RS1000403832 (10:101810630 C>T), RS1000468334 (10:101803445 T>A,C), RS1000514804 (10:101785269 C>T), RS1000605470 (10:101808107 C>CTG), RS1000681943 (10:101809508 G>A,C), RS1000808867 (10:101798409 T>C,G), RS1000914572 (10:101785083 C>A), RS1001140684 (10:101784439 CACG>C), RS1001162679 (10:101815692 A>C), RS1001170440 (10:101784242 C>T), RS1001197606 (10:101791793 A>G)

Disease associations

OMIM: gene MIM:604039 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST009524_180	Household income (MTAG)	1.000000e-08
GCST010138_11	Raw vegetable consumption	3.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0009695	household income
EFO:0008111	diet measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5921 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 21 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL5095251	CEPEROGNASTAT	2	21

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Hydrolases & Lipases

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
ceperognastat	Inhibition	8.63	pIC50
MK-8719	Inhibition	8.1	pKi
thiamet-G	Inhibition	7.68	pKi

Binding affinities (BindingDB)

309 measured of 373 human assays (373 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
US8901087, 2	KI	0.05 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
US9695197, 4	KI	0.11 nM	US-9695197: Glycosidase inhibitors and uses thereof
US8901087, 27	KI	0.12 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,4R,5R,6R,7aS)-2-(azetidin-1-yl)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydro-1,3-benzoxazole-4,5-diol	KI	0.13 nM	US-9120781: Selective glycosidase inhibitors and uses thereof
US8901087, 191	KI	0.14 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aS,4S,5S,6S,7aR)-2-(dimethylamino)-6-[(1R)-1-hydroxyethyl]-3a,4,5,6,7,7a-hexahydro-1,3-benzothiazole-4,5-diol	KI	0.14 nM	US-9126957: Selective glycosidase inhibitors and uses thereof
US8901087, 95	KI	0.16 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-5-((R)-1-(4- benzylbenzyloxy)-2,2,2- trifluoroethyl)-2-(methylamino)- 5,6,7,7a-tetrahydro-3aH- pyrano[3,2-d]thiazole-6,7-diol	KI	0.16 nM	US-9611275: Permeable glycosidase inhibitors and uses thereof
(3aR,5R,6S,7R,7aR)-2-(dimethylamino)-5-[(1S)-1-hydroxyethyl]-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	KI	0.17 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
US8901087, 97	KI	0.17 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,5R,6S,7R,7aR)-2-(azetidin-1-yl)-5-[(1S)-1-hydroxyethyl]-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	KI	0.18 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-2-(dimethylamino)-5-((R)-1-methoxyethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazole-6,7-diol & (3aR,5S,6S,7R,7aR)-2-(dimethylamino)-5-((S)-1-methoxyethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazole-6,7-diol	KI	0.19 nM	US-9611275: Permeable glycosidase inhibitors and uses thereof
[(3aR,5S,6S,7S,7aR)-2-(dimethylamino)-7-phenylmethoxy-6-(phenylmethoxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazol-5-yl]-(1,3-dithian-2-yl)methanol	KI	0.19 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
US9120781, 26	KI	0.2 nM	US-9120781: Selective glycosidase inhibitors and uses thereof
(3aR,5R,6S,7R,7aR)-2-(dimethylamino)-5-[(1S)-1-hydroxyprop-2-enyl]-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	KI	0.22 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,4R,5R,6R,7aS)-2-(dimethylamino)-6-[(1S)-1-hydroxyethyl]-3a,4,5,6,7,7a-hexahydro-1,3-benzoxazole-4,5-diol	KI	0.26 nM	US-9126957: Selective glycosidase inhibitors and uses thereof
US9126957, 6	KI	0.26 nM	US-9126957: Selective glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-2-(dimethylamino)-5-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	KI	0.3 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,5R,6S,7R,7aR)-2-(dimethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	KI	0.3 nM	US-9815861: Selective glycosidase inhibitors and uses thereof
(3aR,5R,6R,7S,7aR)-2-(dimethylamino)-7-fluoro-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazol-6-ol	KI	0.3 nM	US-9409924: Selective glycosidase inhibitors and uses thereof
US9409924, 34	KI	0.3 nM	US-9409924: Selective glycosidase inhibitors and uses thereof
(3aR,5R,6S,7R,7aR)-2-[ethyl(methyl)amino]-5-(1-hydroxyethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	KI	0.33 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
US8901087, 13	KI	0.4 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
US9409924, (3aR,5R,6R,7S,7aR)-2-(ethylamino)-7-fluoro-5-(hydroxymethyl)-3aH,5H,6H,7H,7aH-pyrano[3,2-d][1,3]thiazol-6-ol	KI	0.4 nM	US-9409924: Selective glycosidase inhibitors and uses thereof
(3AR,5R,6S,7R,7AR)-2-(ETHYLAMINO)-5-(HYDROXYMETHYL)-5,6,7,7A-TETRAHYDRO-3AH-PYRANO[3,2-D][1,3]THIAZOLE-6,7-DIOL	KI	0.4 nM	US-9243020: Selective glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-2-[ethyl(methyl)amino]-5-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	KI	0.44 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,5R,6S,7R,7aR)-2-(dimethylamino)-5-[(1S)-1-hydroxy-2-methylprop-2-enyl]-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	KI	0.45 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-2- (dimethylamino)-5-((R)-2,2,2- trifluoro-1-(4-methoxy-3,5- dimethylbenzyloxy)ethyl)- 5,6,7,7a-tetrahydro-3aH- pyrano[3,2-d]thiazole-6,7-diol	KI	0.45 nM	US-9611275: Permeable glycosidase inhibitors and uses thereof
(3aR,5R,6S,7R,7aR)-2-(azetidin-1-yl)-5-[(1S)-1-hydroxyprop-2-enyl]-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	KI	0.5 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,4R,5R,6R,7aS)-2-(dimethylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydro-1,3-benzothiazole-4,5-diol	KI	0.5 nM	US-9120781: Selective glycosidase inhibitors and uses thereof
US9243020, 17	KI	0.5 nM	US-9815861: Selective glycosidase inhibitors and uses thereof
(3aR,5R,6S,7R,7aR)-5-[(1S)-1-hydroxyethyl]-2-pyrrolidin-1-yl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	KI	0.53 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-2- (methylamino)-5-((R)-2,2,2- trifluoro-1-(4-(3- fluoropropyl)benzyloxy)ethyl)- 5,6,7,7a-tetrahydro-3aH- pyrano[3,2-d]thiazole-6,7-diol	KI	0.59 nM	US-9611275: Permeable glycosidase inhibitors and uses thereof
US9120781, 9	KI	0.6 nM	US-9120781: Selective glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-2- (dimethylamino)-5-((R)-2,2,2- trifluoro-1-(4-(2- fluoroethyl)benzyloxy)ethyl)- 5,6,7,7a-tetrahydro-3aH- pyrano[3,2-d]thiazole-6,7-diol	KI	0.61 nM	US-9611275: Permeable glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-2- (dimethylamino)-5-((R)-2,2,2- trifluoro-1-(4-(2- fluoroethoxy)benzyloxy)ethyl)- 5,6,7,7a-tetrahydro-3aH- pyrano[3,2-d]thiazole-6,7-diol	KI	0.65 nM	US-9611275: Permeable glycosidase inhibitors and uses thereof
US8901087, 8	KI	0.68 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
N-[1-(7-{bis[(4-methoxyphenyl)methyl]amino}heptyl)-4,5-dihydroxy-6-(hydroxymethyl)piperidin-3-yl]acetamide, 4	KI	0.69 nM
US8901087, 25	KI	0.7 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
US8901087, 53	KI	0.7 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,4R,5R,6S,7aS)-2-(azetidin-1-yl)-6-(difluoromethyl)-3a,4,5,6,7,7a-hexahydro-1,3-benzoxazole-4,5-diol	KI	0.7 nM	US-9199949: Selective glycosidase inhibitors and uses thereof
US9409924, 38	KI	0.7 nM	US-9409924: Selective glycosidase inhibitors and uses thereof
(3aR,5R,6S,7S,7aR)-5- (hydroxymethyl)-2-(methylamino)- 5,6,7,7a-tetrahydro-3aH-pyrano[3,2- d]thiazole-6,7-diol	KI	0.7 nM	US-9701693: Selective glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-2- (methylamino)-5-((R)-2,2,2- trifluoro-1-(4-(2- fluoroethyl)benzyloxy)ethyl)- 5,6,7,7a-tetrahydro-3aH- pyrano[3,2-d]thiazole-6,7-diol	KI	0.71 nM	US-9611275: Permeable glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-2- (dimethylamino)-5-((R)-2,2,2- trifluoro-1-(4-(3- fluoropropyl)benzyloxy)ethyl)- 5,6,7,7a-tetrahydro-3aH- pyrano[3,2-d]thiazole-6,7-diol	KI	0.78 nM	US-9611275: Permeable glycosidase inhibitors and uses thereof
US8901087, 181	KI	0.8 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
US8901087, 141	KI	0.82 nM	US-8901087: Selective glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-5-((R)-1-(4-(allyloxy)benzyloxy)-2,2,2-trifluoroethyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazole-6,7-diol	KI	0.82 nM	US-9611275: Permeable glycosidase inhibitors and uses thereof
(3aR,5S,6S,7R,7aR)-2- (dimethylamino)-5-((R)-2,2,2- trifluoro-1-(4-methoxy-3- (trifluoromethyl)benzyloxy)ethyl)- 5,6,7,7a-tetrahydro-3aH- pyrano[3,2-d]thiazole-6,7-diol	KI	0.84 nM	US-9611275: Permeable glycosidase inhibitors and uses thereof
US8901087, 3	KI	0.9 nM	US-8901087: Selective glycosidase inhibitors and uses thereof

ChEMBL bioactivities

985 potent at pChembl≥5 of 991 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.30	Ki	0.05	nM	CHEMBL3647355
10.12	Ki	0.075	nM	CHEMBL5978885
10.02	Ki	0.095	nM	CHEMBL5982879
9.96	Ki	0.11	nM	CHEMBL6019753
9.93	Ki	0.117	nM	CHEMBL5833418
9.92	Ki	0.12	nM	CHEMBL3647362
9.89	Ki	0.13	nM	CHEMBL4109135
9.85	Ki	0.14	nM	CHEMBL3647388
9.85	Ki	0.14	nM	CHEMBL3952267
9.80	Ki	0.16	nM	CHEMBL3647380
9.80	Ki	0.16	nM	CHEMBL6029490
9.78	Ki	0.167	nM	CHEMBL5978885
9.77	Ki	0.17	nM	CHEMBL3647354
9.77	Ki	0.17	nM	CHEMBL3647381
9.74	Ki	0.18	nM	CHEMBL3647375
9.72	Ki	0.19	nM	CHEMBL3647392
9.72	Ki	0.19	nM	CHEMBL5906193
9.70	Ki	0.2	nM	CHEMBL4115664
9.67	IC50	0.214	nM	CHEMBL4779747
9.66	Ki	0.22	nM	CHEMBL3647370
9.62	Ki	0.241	nM	CHEMBL6064515
9.59	Ki	0.26	nM	CHEMBL3986688
9.59	Ki	0.26	nM	CHEMBL3931073
9.57	Ki	0.268	nM	CHEMBL6057396
9.54	Ki	0.287	nM	CHEMBL5828721
9.53	Ki	0.294	nM	CHEMBL5782940
9.52	Ki	0.3	nM	CHEMBL3647359
9.52	Ki	0.3	nM	CHEMBL4112819
9.52	Ki	0.3	nM	CHEMBL4110353
9.52	Ki	0.3	nM	CHEMBL3929320
9.49	Ki	0.324	nM	CHEMBL5944832
9.48	Ki	0.33	nM	CHEMBL3647368
9.47	IC50	0.34	nM	CHEMBL5591488
9.44	Ki	0.36	nM	CHEMBL4443587
9.41	IC50	0.385	nM	CHEMBL4759587
9.41	Ki	0.392	nM	CHEMBL5783742
9.41	Ki	0.387	nM	CHEMBL5861625
9.41	Ki	0.389	nM	CHEMBL5752657
9.40	Ki	0.4	nM	CHEMBL3647360
9.40	Ki	0.4	nM	CHEMBL1213603
9.40	Ki	0.4	nM	CHEMBL4108448
9.39	IC50	0.41	nM	CHEMBL1213603
9.39	Ki	0.41	nM	CHEMBL1213603
9.39	Ki	0.411	nM	CHEMBL5879675
9.37	IC50	0.43	nM	CHEMBL5591695
9.37	Ki	0.427	nM	CHEMBL5789908
9.37	Ki	0.43	nM	CHEMBL5777939
9.36	Ki	0.44	nM	CHEMBL3647390
9.35	Ki	0.45	nM	CHEMBL3647371
9.35	Ki	0.45	nM	CHEMBL5763051

PubChem BioAssay actives

255 with measured affinity, of 400 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-[2-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5-methylpyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl]ethanone	1710173: Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay	ic50	0.0002	uM
N-[5-[[4-[2-(1,2,3,4-tetrahydro-1,7-naphthyridin-6-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0003	uM
(3aR,5R,6S,7R,7aR)-2-ethylimino-5-(hydroxymethyl)-1,3a,5,6,7,7a-hexahydropyrano[3,2-d][1,3]thiazole-6,7-diol	1527147: Inhibition of human O-GlcNAcase	ic50	0.0004	uM
1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethyl]-5-methylpyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl]ethanone	1710173: Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay	ic50	0.0004	uM
N-[5-[[4-[2-[2-(dimethylamino)pyrimidin-5-yl]ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0004	uM
(3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	1558062: Inhibition of recombinant human OGA	ki	0.0004	uM
1-[2-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5-methylpyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]ethanone	1710173: Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay	ic50	0.0005	uM
1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethyl]-5-methylpyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]ethanone	1710173: Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay	ic50	0.0005	uM
(3aR,5R,6R,7S,7aR)-7-fluoro-5-(hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazol-6-ol	1558062: Inhibition of recombinant human OGA	ki	0.0005	uM
(3aR,5S,6S,7R,7aR)-5-(fluoromethyl)-2-methylimino-1,3a,5,6,7,7a-hexahydropyrano[3,2-d][1,3]thiazole-6,7-diol	1558062: Inhibition of recombinant human OGA	ki	0.0006	uM
1-[3-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5-methylpyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl]ethanone	1710173: Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay	ic50	0.0006	uM
N-[5-[[4-[2-(8-methylquinolin-6-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0007	uM
1-[6-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5-methylpyrrolidin-3-yl]oxy-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]ethanone	1710173: Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay	ic50	0.0008	uM
N-[5-[[4-[2-(1,2,3,4-tetrahydroquinolin-7-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0008	uM
N-[5-[[4-[2-(7-methylquinolin-6-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0015	uM
N-[5-[[4-[2-(2-oxo-3,4-dihydro-1H-quinolin-5-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0017	uM
N-[5-[[4-[2-(1-benzofuran-7-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0018	uM
N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,3,4-oxadiazol-2-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0021	uM
N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114327: Inhibition of full length N-terminal his-tagged human OGA expressed in baculovirus expression system preincubated for for 30 mins followed by substrate addition and measured after 60 mins by fluorescence based analysis	ic50	0.0024	uM
(3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(dimethylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	1558062: Inhibition of recombinant human OGA	ki	0.0024	uM
(3aR,5R,6S,7R,7aR)-5-(hydroxymethyl)-2-[methyl(prop-2-enyl)amino]-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	1558062: Inhibition of recombinant human OGA	ki	0.0028	uM
(3aR,5R,6R,7R,7aR)-7-fluoro-5-(hydroxymethyl)-2-methylimino-1,3a,5,6,7,7a-hexahydropyrano[3,2-d][1,3]thiazol-6-ol	1558062: Inhibition of recombinant human OGA	ki	0.0030	uM
N-[5-[[4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0030	uM
N-[5-[[4-[2-(8-fluoro-1,2,3,4-tetrahydroquinolin-6-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0032	uM
(3aR,5R,6S,7R,7aR)-2-(azetidin-1-yl)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	1558062: Inhibition of recombinant human OGA	ki	0.0033	uM
N-[5-[[4-[2-[6-(dimethylamino)-3-pyridinyl]ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0035	uM
N-[5-[[4-[2-[6-(trifluoromethyl)pyrimidin-4-yl]ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0036	uM
N-[5-[[(5S)-2-(2,6-dimethyl-4-pyridinyl)-2,7-diazaspiro[4.4]nonan-7-yl]methyl]-1,3-thiazol-2-yl]acetamide	1537422: Inhibition of recombinant human full length OGA using FM-GlcNAc as substrate preincubated for 60 mins followed by substrate addition and measured after 6 hrs by fluorescence assay	ic50	0.0037	uM
N-[5-[[4-[2-(2-pyrrolidin-1-ylpyrimidin-5-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0037	uM
N-[5-[[2-(3,5-dimethyl-2-pyridinyl)-2,7-diazaspiro[4.4]nonan-7-yl]methyl]-1,3-thiazol-2-yl]acetamide	1537422: Inhibition of recombinant human full length OGA using FM-GlcNAc as substrate preincubated for 60 mins followed by substrate addition and measured after 6 hrs by fluorescence assay	ic50	0.0039	uM
(2E)-N-[(5R,6R,7R,8S)-6,7-dihydroxy-5-(hydroxymethyl)-2-(2-phenylethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-8-yl]penta-2,4-dienamide	1378936: Competitive inhibition of human O-GlcNAcase by Lineweaver-Burk analysis	ki	0.0041	uM
N-[5-[[4-[2-(2,6-dimethyl-3-pyridinyl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0044	uM
N-[5-[[4-[2-(5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0046	uM
N-[5-[[4-[2-(1,2,3,4-tetrahydroquinolin-6-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0049	uM
(3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(propylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	1558062: Inhibition of recombinant human OGA	ki	0.0053	uM
N-[5-[[4-[2-(4,6-dimethyl-2-pyridinyl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0054	uM
(3aR,5R,6S,7R,7aR)-2-[ethyl(methyl)amino]-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	1558062: Inhibition of recombinant human OGA	ki	0.0055	uM
(3aR,5R,6S,7R,7aR)-2-(2-fluoroethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	1558062: Inhibition of recombinant human OGA	ki	0.0056	uM
N-[5-[[2-(2,6-dimethyl-4-pyridinyl)-2,7-diazaspiro[4.4]nonan-7-yl]methyl]-1,3-thiazol-2-yl]acetamide	1537422: Inhibition of recombinant human full length OGA using FM-GlcNAc as substrate preincubated for 60 mins followed by substrate addition and measured after 6 hrs by fluorescence assay	ic50	0.0060	uM
(3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-ethylimino-1,3a,5,6,7,7a-hexahydropyrano[3,2-d][1,3]thiazole-6,7-diol	1527147: Inhibition of human O-GlcNAcase	ic50	0.0079	uM
N-[5-[[4-[2-(2-oxo-3,4-dihydro-1H-quinolin-6-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0080	uM
N-[5-[[4-[2-[2-(trifluoromethyl)pyrimidin-5-yl]ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0087	uM
N-[5-[[4-[2-(6-pyrrolidin-1-yl-3-pyridinyl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0088	uM
N-[5-[[4-[2-(2,3-dihydro-1-benzofuran-5-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0089	uM
N-[5-[[4-[2-(7-fluoro-1,2,3,4-tetrahydroquinolin-6-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0089	uM
(3aR,5S,6S,7R,7aR)-2-(dimethylamino)-5-(fluoromethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	1558062: Inhibition of recombinant human OGA	ki	0.0090	uM
(3aR,5R,6S,7aR)-5-(hydroxymethyl)-2-(methylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazol-6-ol	1558062: Inhibition of recombinant human OGA	ki	0.0094	uM
N-[5-[[4-[2-(1,3-benzodioxol-5-yl)ethynyl]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide	2114285: Inhibition of GST-tagged human recombinant OGA using fuoresceinmono-beta-o-N-acetylglucosarnine as substrate incubated for 60 mins under dark condition by microplate reader based analysis	ic50	0.0095	uM
(3aR,5R,6S,7R,7aR)-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol	515842: Inhibition of human O-GlcNAcase after 5 mins by Lineweaver-Burke plot analysis	ki	0.0100	uM
N-[5-[4-[(1S)-1-(1,3-benzodioxol-5-yl)ethyl]piperazin-1-yl]-1,3,4-thiadiazol-2-yl]acetamide	2114326: Inhibition of human OGA	ic50	0.0102	uM

CTD chemical–gene interactions

74 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases expression, affects expression	6
bisphenol A	decreases expression, increases expression, increases methylation	4
sodium arsenite	decreases expression, increases expression	4
Acetaminophen	affects expression, increases expression	3
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression, decreases expression	3
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
bisphenol S	increases expression, affects cotreatment, decreases expression	2
Leflunomide	increases expression	2
Rotenone	decreases expression	2
Tretinoin	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, decreases expression	1
dicrotophos	decreases expression	1
beauvericin	increases expression	1
triphenyl phosphate	affects expression	1
deoxynivalenol	increases expression	1
quercitrin	increases expression	1
trichostatin A	affects expression	1
methylparaben	increases expression	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
nickel chloride	increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	decreases expression	1
tamibarotene	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chloropicrin	increases expression	1
K 7174	increases expression	1

ChEMBL screening assays

89 unique, capped per target: 89 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1218573	Binding	Inhibition of human O-GlcNAcase	A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. — Nat Chem Biol

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1ZH	Abcam HeLa OGA KO	Cancer cell line	Female
CVCL_SY28	HAP1 MGEA5 (-) 1	Cancer cell line	Male
CVCL_XQ53	HAP1 MGEA5 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.